Urovant Sciences (UROV) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Urovant Sciences (NASDAQ:UROV) in a report released on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $28.00 price objective on the stock.

Separately, Zacks Investment Research raised Urovant Sciences from a sell rating to a hold rating in a report on Thursday, February 21st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $19.55.

UROV stock opened at $13.75 on Monday. Urovant Sciences has a twelve month low of $4.05 and a twelve month high of $14.32.



Urovant Sciences (NASDAQ:UROV) last issued its quarterly earnings results on Wednesday, February 13th. The company reported ($0.87) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.09) by $0.22. On average, analysts anticipate that Urovant Sciences will post -4.21 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC acquired a new stake in shares of Urovant Sciences during the fourth quarter worth $37,000. Two Sigma Investments LP acquired a new stake in shares of Urovant Sciences during the fourth quarter worth $72,000. Weiss Multi Strategy Advisers LLC lifted its holdings in shares of Urovant Sciences by 38.2% during the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 15,000 shares of the company’s stock worth $99,000 after purchasing an additional 4,146 shares during the period. Point72 Hong Kong Ltd acquired a new stake in shares of Urovant Sciences during the third quarter worth $147,000. Finally, Man Group plc acquired a new stake in shares of Urovant Sciences during the third quarter worth $300,000. 22.77% of the stock is owned by hedge funds and other institutional investors.

Urovant Sciences Company Profile

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Featured Story: What are retained earnings?

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.